|
Report Date : |
25.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
WEI MING PHARMACEUTICAL MFG. CO., LTD. |
|
|
|
|
Registered Office : |
No. 3, Lane 98, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
16.08.1962 |
|
|
|
|
Com. Reg. No.: |
11653105 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and trade of pharmaceutical products |
|
|
|
|
No. of Employees : |
About 80 Employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Taiwan |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
|
|
Supplied Address: |
|
|
Telephone Number: |
|
|
Fax Number: |
|
|
E-mail: |
Notes:
The exact name and address are as above.
|
Credit Opinion: |
Subject was incorporated on
|
Name |
Subscription
Amount |
|
Daxiong Ye |
11,744,905 |
|
Taihu Chen |
|
|
283,950 |
|
|
Meihui Liuye |
1,311,010 |
The information
above is that of subject’s major shareholders.
Factories
|
1 |
|
|
Name |
Nan Kang Pharmaceutical Raw Material Factory |
|
Address |
Taiwan, R.O.C |
|
2 |
|
|
Name |
Tansui Raw Material GMP Factory |
|
Address |
Tansui, Taiwan, R.O.C |
Core
Management
Directors
|
1 |
|
|
Name |
Daxiong Ye |
|
Position |
Board of Chairman |
|
2 |
|
|
Name |
Taihu Chen |
|
Position |
Director |
|
3 |
|
|
Name |
Meihui Liuye |
|
Position |
Director |
|
4 |
|
|
Name |
Qinglong Chen |
|
Position |
Supervisor |
Personnel
Structure
|
Total Employees |
About 80 Employees |
Offices
& Factories
|
|
Headquarters |
|
Add |
Production
Information
l
Subject is a manufacturer of medical products and
the related products with the production activities
Purchase
Information
l
The registered activities of subject:
|
Business Code |
Details |
|
F108031 |
Wholesale of
medical device |
|
F208031 |
Retail of
medical device |
|
ZZ99999 |
Besides licensed
business, all other business items those are not banned or restricted. |
l
The components and raw material for production are
mostly purchased from abroad.
l
Subject is mainly engaged in manufacturing and trading
of medical products and the related products.
l
Subject introduced that it also imports the
products pharmaceutical chemicals from Europe, U.S.A and Japan.
l
Subject introduced that major self-manufacturing
products sold as following:
|
|
Product |
|
1 |
Active
Agents |
|
2 |
Fillers &
Diluents |
|
3 |
Coating
Materials |
|
4 |
Excipients:
Lubricants & Flow-aids |
|
5 |
Surfactants /
Solubilizers / Emulsifiers |
|
6 |
Polymers |
|
7 |
Fat & Oil
Components |
|
8 |
Humectants |
|
9 |
Sunscreen Agents |
|
10 |
Vitamins &
Anti-oxidants |
|
11 |
Industrial
Materials |
|
12 |
Others |
l
Subject introduced some brands it imports, such as
BASF, IPS Italy, EASTMAN, FUJI CHEMICAL and so on.
l
Subject introduced that it also trades the cosmeceutical
products, and the brand named Biopeutic.
l
Subject’s selling territory covers all over the
world.
Import and export
right:
|
Import right |
Yes |
|
Export right |
Yes |
Subject declined to disclose the settlements information, and from other
sources, we couldn’t obtain the information, either.
Subject has no obligations to disclose its financial statements to the
third party according to the relevant policy in Taiwan and the only source from
which we can obtain the information is the subject itself.
Subject’s relevant staff Ms. Liu declined to disclose its financials
citing the grounds of company’s confidentiality; from other source we can not
obtain the relevant information, either.
The bankers’ information is not available from the subject or other
sources.
Mortgage
No chattel mortgage record of subject has been found within the recent 3
months.
Lawsuit
Up to date of reporting,
no existing or latent litigation of the subject has been found.
|
Name |
Ms. Liu |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.01 |
|
|
1 |
Rs.86.89 |
|
Euro |
1 |
Rs.67.83 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.